The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors for solid tumors: a systemic review and meta-analysis

Chiara Ciccaresea Medical Oncology, Comprehensive Cancer Center, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ItalyView further author information

Annunziato Angheloneb Medical Oncology, Università Cattolica del Sacro Cuore, Rome, ItalyView further author information

Alessio Stefanib Medical Oncology, Università Cattolica del Sacro Cuore, Rome, ItalyView further author information

Antonio Cigliolab Medical Oncology, Università Cattolica del Sacro Cuore, Rome, ItalyView further author information

Alessandro Strusib Medical Oncology, Università Cattolica del Sacro Cuore, Rome, ItalyView further author information

Filippo D’Agostinob Medical Oncology, Università Cattolica del Sacro Cuore, Rome, ItalyView further author information

Emilio Briaa Medical Oncology, Comprehensive Cancer Center, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy;b Medical Oncology, Università Cattolica del Sacro Cuore, Rome, ItalyView further author information

Roberto Iacovellia Medical Oncology, Comprehensive Cancer Center, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy;b Medical Oncology, Università Cattolica del Sacro Cuore, Rome, ItalyCorrespondence[email protected]
View further author information

Giampaolo Tortoraa Medical Oncology, Comprehensive Cancer Center, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy;b Medical Oncology, Università Cattolica del Sacro Cuore, Rome, ItalyView further author information

show all

The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors for solid tumors: a systemic review and meta-analysis

Supplemental Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors for solid tumors: a systemic review and meta-analysis

Supplemental Material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date